main inclusion criteria: * pasc syndrome in accordance with nice criteria with neuropsychiatric symptoms still occurring \>12 weeks after their first appearance. * has had a sars-cov-2-positive diagnostic test (using a validated sars-cov-2 antigen, reverse transcription polymerase chain reaction \[rt-pcr\], or other molecular diagnostic assay, and an appropriate sample such as nasopharyngeal \[np\], nasal, oropharyngeal \[op\], or saliva). in case that the local standard of care did not foresee the previously mentioned tests, a confirmed sars-cov-2 nucleocapsid or membrane antibody test associated to a medical report documenting the date of covid-19 clinical diagnostic, will be accepted. * promis fatigue sf 7a total raw score ≥21 with onset of fatigue post coronavirus disease 2019 (covid-19) infection. * patients affected with at least one of the following measures of objective impairment of cognitive function or of quality of life as defined by: i. token motor test ≥1 z-score below the age/sex-adjusted mean ii. eq5d-5l: presence of at least 1 score ≥3 in any of the 5 variables of eq5d-5l questionnaire (mobility; self-care; usual activities; pain/discomfort; anxiety/depression) iii. pqd-20 ≥27 * herv-w env positive as defined by automated capillary western system, specific signal level over background noise (s/n) \>1. main

main inclusion criteria: * pasc syndrome in accordance with nice criteria with neuropsychiatric symptoms still occurring \>12 weeks after their first appearance. * has had a sars-cov-2-positive diagnostic test (using a validated sars-cov-2 antigen, reverse transcription polymerase chain reaction \[rt-pcr\], or other molecular diagnostic assay, and an appropriate sample such as nasopharyngeal \[np\], nasal, oropharyngeal \[op\], or saliva). in case that the local standard of care did not foresee the previously mentioned tests, a confirmed sars-cov-2 nucleocapsid or membrane antibody test associated to a medical report documenting the date of covid-19 clinical diagnostic, will be accepted. * promis fatigue sf 7a total raw score ≥21 with onset of fatigue post coronavirus disease 2019 (covid-19) infection. * patients affected with at least one of the following measures of objective impairment of cognitive function or of quality of life as defined by: i. token motor test ≥1 z-score below the age/sex-adjusted mean ii. eq5d-5l: presence of at least 1 score ≥3 in any of the 5 variables of eq5d-5l questionnaire (mobility; self-care; usual activities; pain/discomfort; anxiety/depression) iii. pqd-20 ≥27 * herv-w env positive as defined by automated capillary western system, specific signal level over background noise (s/n) \>1. main

main inclusion criteria: pasc syndrome in accordance with nice criteria with neuropsychiatric symptoms still occurring >12 weeks after their first appearance. has had a sars-cov-2-positive diagnostic test (using a validated sars-cov-2 antigen, reverse transcription polymerase chain reaction [rt-pcr], or other molecular diagnostic assay, and an appropriate sample such as nasopharyngeal [np], nasal, oropharyngeal [op], or saliva). in case that the local standard of care did not foresee the previously mentioned tests, a confirmed sars-cov-2 nucleocapsid or membrane antibody test associated to a medical report documenting the date of covid-19 clinical diagnostic, will be accepted. promis fatigue sf 7a total raw score ≥21 with onset of fatigue post coronavirus disease 2019 (covid-19) infection. patients affected with at least one of the following measures of objective impairment of cognitive function or of quality of life as defined by: i. token motor test ≥1 z-score below the age/sex-adjusted mean ii. eq5d-5l: presence of at least 1 score ≥3 in any of the 5 variables of eq5d-5l questionnaire (mobility; self-care; usual activities; pain/discomfort; anxiety/depression) iii. pqd-20 ≥27 herv-w env positive as defined by automated capillary western system, specific signal level over background noise (s/n) >1. main

main inclusion criteria: pasc syndrome in accordance with nice criteria with neuropsychiatric symptoms still occurring >12 weeks after their first appearance. has had a sars-cov-2-positive diagnostic test (using a validated sars-cov-2 antigen, reverse transcription polymerase chain reaction [rt-pcr], or other molecular diagnostic assay, and an appropriate sample such as nasopharyngeal [np], nasal, oropharyngeal [op], or saliva). in case that the local standard of care did not foresee the previously mentioned tests, a confirmed sars-cov-2 nucleocapsid or membrane antibody test associated to a medical report documenting the date of covid-19 clinical diagnostic, will be accepted. promis fatigue sf 7a total raw score ≥21 with onset of fatigue post coronavirus disease 2019 (covid-19) infection. patients affected with at least one of the following measures of objective impairment of cognitive function or of quality of life as defined by: i. token motor test ≥1 z-score below the age/sex-adjusted mean ii. eq5d-5l: presence of at least 1 score ≥3 in any of the 5 variables of eq5d-5l questionnaire (mobility; self-care; usual activities; pain/discomfort; anxiety/depression) iii. pqd-20 ≥27 herv-w env positive as defined by automated capillary western system, specific signal level over background noise (s/n) >1. main

main inclusion criteria: pasc syndrome in accordance with nice criteria with with neuropsychiatric symptoms still occurring >12 to 96 weeks after their first appearance. has had a sars-cov-2-positive diagnostic test (using a validated sars-cov-2 antigen, reverse transcription polymerase chain reaction [rt-pcr], or other molecular diagnostic assay, and an appropriate sample such as nasopharyngeal [np], nasal, oropharyngeal [op], or saliva). in case that the local standard of care did not foresee the previously mentioned tests, a confirmed sars-cov-2 nucleocapsid or membrane antibody test associated to a medical report documenting the date of covid-19 clinical diagnostic, will be accepted. promis fatigue sf 7a total raw score ≥21 with onset of fatigue post coronavirus disease 2019 (covid-19) infection. patients affected with at least one of the following measures of objective impairment of cognitive function or of quality of life as defined by: i. token motor test ≥1 z-score below the age/sex-adjusted mean ii. eq5d-5l: presence of at least 1 score ≥3 in any of the 5 variables of eq5d-5l questionnaire (mobility; self-care; usual activities; pain/discomfort; anxiety/depression) iii. pqd-20 ≥27 herv-w env positive as defined by automated capillary western system, specific signal level over background noise (s/n) >1. main

main inclusion criteria: pasc syndrome in accordance with nice criteria with with neuropsychiatric symptoms still occurring >12 to 96 weeks after their first appearance. has had a sars-cov-2-positive diagnostic test (using a validated sars-cov-2 antigen, reverse transcription polymerase chain reaction [rt-pcr], or other molecular diagnostic assay, and an appropriate sample such as nasopharyngeal [np], nasal, oropharyngeal [op], or saliva). in case that the local standard of care did not foresee the previously mentioned tests, a confirmed sars-cov-2 nucleocapsid or membrane antibody test associated to a medical report documenting the date of covid-19 clinical diagnostic, will be accepted. promis fatigue sf 7a total raw score ≥21 with onset of fatigue post coronavirus disease 2019 (covid-19) infection. patients affected with at least one of the following measures of objective impairment of cognitive function or of quality of life as defined by: i. token motor test ≥1 z-score below the age/sex-adjusted mean ii. eq5d-5l: presence of at least 1 score ≥3 in any of the 5 variables of eq5d-5l questionnaire (mobility; self-care; usual activities; pain/discomfort; anxiety/depression) iii. pqd-20 ≥27 herv-w env positive as defined by automated capillary western system, specific signal level over background noise (s/n) >1. main

main inclusion criteria: pasc syndrome in accordance with nice criteria with symptoms still occurring >12 to 96 weeks post diagnostic rt-pcr date promis fatigue sf 7a total raw score ≥21 with onset of fatigue post coronavirus disease 2019 (covid-19) infection patients affected with at least one of the following measures of objective impairment of cognitive function or of quality of life as defined by: i. token motor test ≥1 z-score below the age/sex-adjusted mean ii. eq5d-5l: presence of at least 1 score ≥3 in any of the 5 variables of eq5d-5l questionnaire (mobility; self-care; usual activities; pain/discomfort; anxiety/depression) iii. pqd-20 ≥27 herv-w env positive as defined by automated capillary western system, specific signal level over background noise (s/n) >1. main

main inclusion criteria: pasc syndrome in accordance with nice criteria with symptoms still occurring >12 to 96 weeks post diagnostic rt-pcr date promis fatigue sf 7a total raw score ≥21 with onset of fatigue post coronavirus disease 2019 (covid-19) infection patients affected with at least one of the following measures of objective impairment of cognitive function or of quality of life as defined by: i. token motor test ≥1 z-score below the age/sex-adjusted mean ii. eq5d-5l: presence of at least 1 score ≥3 in any of the 5 variables of eq5d-5l questionnaire (mobility; self-care; usual activities; pain/discomfort; anxiety/depression) iii. pqd-20 ≥27 herv-w env positive as defined by automated capillary western system, specific signal level over background noise (s/n) >1. main

main inclusion criteria: pasc syndrome in accordance with nice criteria with symptoms still occurring >12 to 48 weeks post diagnostic rt-pcr date promis fatigue sf 7a total raw score ≥21 with onset of fatigue post coronavirus disease 2019 (covid-19) infection patients affected with at least one of the following measures of objective impairment of cognitive function or of quality of life as defined by: i. token motor test ≥1 z-score below the age/sex-adjusted mean ii. eq5d-5l: presence of at least 1 score ≥3 in any of the 5 variables of eq5d-5l questionnaire (mobility; self-care; usual activities; pain/discomfort; anxiety/depression) iii. pqd-20 ≥27 herv-w env positive as defined by automated capillary western system, specific signal level over background noise (s/n) >1. main

main inclusion criteria: pasc syndrome in accordance with nice criteria with symptoms still occurring >12 to 48 weeks post diagnostic rt-pcr date promis fatigue sf 7a total raw score ≥21 with onset of fatigue post coronavirus disease 2019 (covid-19) infection patients affected with at least one of the following measures of objective impairment of cognitive function or of quality of life as defined by: i. token motor test ≥1 z-score below the age/sex-adjusted mean ii. eq5d-5l: presence of at least 1 score ≥3 in any of the 5 variables of eq5d-5l questionnaire (mobility; self-care; usual activities; pain/discomfort; anxiety/depression) iii. pqd-20 ≥27 herv-w env positive as defined by automated capillary western system, specific signal level over background noise (s/n) >1. main